Identification of a pharmacological approach to reduce ACE2 expression and development of an in vitro COVID-19 viral entry model
Because of rapid emergence and circulation of the SARS-CoV-2 variants, especially Omicron which shows increased transmissibility and resistant to antibodies, there is an urgent need to develop novel therapeutic drugs to treat COVID-19. In this study we developed an in vitro cellular model to explore...
Saved in:
Main Authors: | Yukinori Endo (Author), Brady T. Hickerson (Author), Natalia A. Ilyushina (Author), Nishant Mohan (Author), Hanjing Peng (Author), Kazuyo Takeda (Author), Raymond P. Donnelly (Author), Wen Jin Wu (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2022-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
by: Arun Bahadur Gurung, et al.
Published: (2021) -
Epithelial and Endothelial Expressions of ACE2: SARS-CoV-2 Entry Routes
by: Ceren Guney, et al.
Published: (2021) -
Molecular docking study of anti-viral FDA-approved drugs as novel entry and replication Ebola viral inhibitors
by: Saghi Sepehri, et al.
Published: (2019) -
Computational guided identification of potential leads from Acacia pennata (L.) Willd. as inhibitors for cellular entry and viral replication of SARS-CoV-2
by: James H. Zothantluanga, et al.
Published: (2021) -
Identification of the dietary supplement capsaicin as an inhibitor of Lassa virus entry
by: Ke Tang, et al.
Published: (2020)